0.9509
Accendra Health Inc stock is traded at $0.9509, with a volume of 2.87M.
It is down -13.55% in the last 24 hours and down -73.66% over the past month.
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
See More
Previous Close:
$1.10
Open:
$1.08
24h Volume:
2.87M
Relative Volume:
2.95
Market Cap:
$73.13M
Revenue:
$4.72B
Net Income/Loss:
$-123.85M
P/E Ratio:
-0.0665
EPS:
-14.2981
Net Cash Flow:
$-303.12M
1W Performance:
-66.04%
1M Performance:
-73.66%
6M Performance:
-57.55%
1Y Performance:
-82.02%
Accendra Health Inc Stock (ACH) Company Profile
Name
Accendra Health Inc
Sector
Industry
Phone
(804) 277-4304
Address
4435 WATERFRONT DRIVE, GLEN ALLEN
Compare ACH vs MCK, COR, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ACH
Accendra Health Inc
|
0.9509 | 93.05M | 4.72B | -123.85M | -303.12M | -14.30 |
|
MCK
Mckesson Corp
|
869.00 | 102.45B | 403.43B | 5.10B | 5.41B | 38.47 |
|
COR
Cencora Inc
|
313.82 | 59.95B | 328.68B | 2.55B | 1.56B | 13.03 |
|
CAH
Cardinal Health Inc
|
235.17 | 54.46B | 250.74B | 1.55B | 4.39B | 6.5398 |
|
HSIC
Henry Schein Inc
|
89.77 | 10.11B | 13.38B | 418.00M | 391.00M | 3.3112 |
|
AHG
Akso Health Group Adr
|
1.27 | 1.26B | 14.85M | -136.07M | 7.25M | -0.4726 |
Accendra Health Inc Stock (ACH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Downgrade | UBS | Buy → Neutral |
| Jul-19-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Oct-13-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-26-22 | Resumed | Citigroup | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Mar-30-22 | Resumed | JP Morgan | Underweight |
| Mar-23-22 | Upgrade | HSBC Securities | Reduce → Hold |
| Apr-08-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-17-20 | Upgrade | UBS | Neutral → Buy |
| Sep-25-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-21-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-14-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-05-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Jan-21-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-07-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-15-19 | Upgrade | CLSA | Underperform → Outperform |
| Sep-06-19 | Reiterated | BofA/Merrill | Neutral |
| Apr-10-19 | Reiterated | BofA/Merrill | Neutral |
| Apr-03-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-01-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Jan-18-19 | Upgrade | HSBC Securities | Hold → Buy |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-15-19 | Upgrade | CLSA | Underperform → Outperform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-12-18 | Downgrade | Goldman | Buy → Neutral |
| Sep-28-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-11-18 | Downgrade | CLSA | Outperform → Sell |
| Apr-10-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-26-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-17 | Downgrade | HSBC Securities | Buy → Hold |
| Mar-24-16 | Upgrade | Goldman | Sell → Neutral |
| Dec-07-15 | Downgrade | Goldman | Neutral → Sell |
| Aug-31-15 | Upgrade | Credit Suisse | Underperform → Neutral |
| Aug-01-12 | Initiated | HSBC Securities | Underweight |
| Aug-05-09 | Upgrade | Citigroup | Sell → Buy |
| Dec-01-08 | Downgrade | HSBC Securities | Neutral → Underweight |
View All
Accendra Health Inc Stock (ACH) Latest News
Accendra Health ready to put weak Q2 in rear view - HME News
Accendra Health Inc (NYSE: ACH) Share Price, ACH Stock News, ACH Share Price & Updates - Kalkine
Accendra Health (NYSE:ACH) Rating Lowered to "Hold" at Robert W. Baird - MarketBeat
Dimensional Fund Advisors LP Buys Shares of 2,606,620 Accendra Health, Inc. $ACH - MarketBeat
Accendra Health, Inc. (ACH) stock price, news, quote and history - Yahoo Finance UK
Baird downgrades Accendra Health stock rating on weak results By Investing.com - Investing.com South Africa
Accendra Health, Inc. (ACH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Baird Downgrades Accendra Health to Neutral From Outperform, Adjusts PT to $1.50 From $6 - marketscreener.com
ACCENDRA HEALTH INC : BAIRD CUTS TO NEUTRAL RATING; CUTS TARGET PRICE TO $1.5 FROM $6 - Bitget
Baird downgrades Accendra Health stock rating on weak results - Investing.com
Accendra Health Chief Executive Edward Pesicka to Retire - Moomoo
Accendra Health Ord Shs (ACH) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Accendra Health tumbles 25% on Q2 miss and weak guidance By Investing.com - Investing.com UK
Accendra Health, Inc. (ACH) Stock Forecasts - Yahoo Finance
Accendra Health Reports 111.1% Wider Q2 2026 Loss at -$0.19/Share - AlphaStreet
Accendra Health Releases Q2 2026 Financial Results - AlphaStreet
Accendra Health says Q2 2026 results miss forecast on weaker revenue growth, slower collections recovery - Bitget
Accendra Health, Inc. Updates Earnings Guidance for the Full Year 2026 - marketscreener.com
Accendra Health seeks next president, CEO - HME News
ACCENDRA HEALTH 2026: Revenue $613.23M, EPS ($1.16) — 10-Q Summary - TradingView
Accendra Health: Expansion opportunities will emerge later in 2026, accelerate in 2027 - HME News
Accendra Health CEO to retire by end of the year - virginiabusiness.com
Earnings call transcript: Accendra Health cuts 2026 outlook as shares sink in Q2 2026 - Investing.com
Accendra Health tumbles 25% on Q2 miss and weak guidance - Investing.com
Accendra Health, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:ACH) 2026-08-10 - Seeking Alpha
Q2 2026 Accendra Health Inc Earnings Call Transcript - GuruFocus
Edward A. Pesicka Plans to Retire as Chief Executive Officer of Accendra Health, Inc - marketscreener.com
Is Accendra Health Inc (ACH) Undervalued After Q2 Earnings Miss? EPS: -$1.16, Revenue: $613.2M; GF Score: 52/100 - GuruFocus
Accendra Health CEO Edward Pesicka to retire by end of 2026 - Investing.com Australia
Accendra Health CEO Ed Pesicka Plans Retirement as Board Begins Successor Search - citybiz
Accendra Health adopts plan to preserve tax loss carryforwards - Investing.com India
Accendra Health adopts plan to preserve tax loss carryforwards By Investing.com - Investing.com Canada
Accendra Health Q2 Revenue Falls to $613.2 Million - Quiver Quantitative
Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value - Business Wire
BRIEF-Accendra Health, Inc Q2 Adjusted EBITDA USD 60.1 Million Vs. IBES Estimate USD 61.3 Million - TradingView
Press Release: Accendra Health Reports Second Quarter 2026 Financial Results - Moomoo
Accendra Health’s Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search - Post Register
Accendra Health earnings missed by $0.31, revenue fell short of estimates - Investing.com Nigeria
Accendra Health Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Accendra Health Q2 Preview: Low Expectations Create Opportunity (NYSE:ACH) - Seeking Alpha
Weekly Recap: Q2 2026 results and Agnes Ansay named VP and CPO - TradingView
Enterprise value to EBITDA forward of Accendra Health, Inc. – NYSE:ACH - TradingView
Accendra Health, Inc. Revenue Breakdown – NYSE:ACH - TradingView
ACH|Accendra Health Ord Shs|Price:3.215|Chg%:+0.075 - TradingKey
Accendra Health names new CIO and chief procurement officer - Investing.com
Accendra Health Announces Leadership Appointments in IT and Procurement - Business Wire
Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call - Business Wire
Accendra Health Ord Shs (ACH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Accendra Health Inc. (ACH) Edges Higher Amid Steady Sector Sentiment – Key Levels in FocusHigh Volume Node - po-news-eg.net
ACH|Accendra Health Ord Shs|Price:2.945|Chg%:-0.465 - tradingkey.com
Paradigm Capital Management Inc. NY Purchases New Position in Accendra Health, Inc. $ACH - MarketBeat
Accendra Health Inc Stock (ACH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):